Moberg Pharma appoints members to the Management team
STOCKHOLM, January 8th, 2019, Moberg Pharma AB (OMX: MOB) announces two additions to the Management team; Annica Magnusson, Senior Director Regulatory Affairs, and Gunilla Wengström, Senior Director Sales & Marketing, both with many years in the company.
Moberg Pharma is pleased to announce appointments of two experienced members to the Management Team. Annica Magnusson, Senior Director Regulatory Affairs, has been with Moberg Pharma since 2013 and had previously held global regulatory affairs positions at e.g. Astra Zeneca. Gunilla Wengström, Senior Director Sales & Marketing, joined Moberg Pharma in 2011, coming from senior sales and marketing positions, both locally and globally, at Orion Pharma and
Mylan AB.
“It is a great pleasure to welcome Annica Magnusson and Gunilla Wengström to the Management Team at Moberg Pharma. Both Annica and Gunilla have assumed increasing senior responsibilities over the last year and I look forward to working together with them to continue to deliver on our strategy,” says Peter Wolpert, CEO of Moberg Pharma AB.
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on January 8th, 2018.
For additional information, please contact:
Peter Wolpert, CEO, telephone: +1 908 432 2203, e-mail: peter.wolpert@mobergpharma.se
Mark Beveridge, VP Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).